Sonja Whitaker
Family Medicine · Pensacola, FLNPI 1528389947
Payments from drug & device makers
Across 93 payments — averaging $99.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$8K
- Novo Nordisk$250
- Lilly USA, LLC$219
- Amgen$163
- AbbVie$134
- AstraZeneca$123
- plus $505 from 14 others
What the payments were for
- Consulting fees$7,67483%
- Travel & lodging$210%
- Food & beverage$1,51116%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $7,818 |
| Novo Nordisk | 13 | $250 |
| Lilly USA, LLC | 13 | $219 |
| Amgen | 12 | $163 |
| AbbVie(2 entities) | 6 | $134 |
| AstraZeneca | 9 | $123 |
| Shire North American Group Inc | 3 | $86 |
| Sunovion Pharmaceuticals Inc. | 5 | $80 |
| Pfizer | 6 | $78 |
| Astellas Pharma US Inc | 3 | $51 |
| Johnson & Johnson | 3 | $36 |
| GSK | 3 | $36 |
| Amarin Pharma, Inc. | 2 | $28 |
| Merck | 2 | $27 |
| Ortho-clinical Diagnostics, Inc. | 1 | $18 |
| Agepha Pharma FZ LLC | 1 | $15 |
| Abbott | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GLASSIA$7,674
How this compares
$9,212 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GlassiaAlpha-1-Proteinase Inhibitor | 23 | $260,355 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 52 | $258,158 |
| OzempicSemaglutide | 139 | $240,048 |
| MounjaroTirzepatide | 155 | $217,740 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 18 | $189,000 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $116,811 |
| EliquisApixaban | 46 | $56,576 |
| XareltoRivaroxaban | 32 | $49,361 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 12 | $46,373 |
| TrulicityDulaglutide | 31 | $46,198 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $43,514 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 50 | $35,314 |
| FarxigaDapagliflozin Propanediol | 18 | $24,706 |
| RybelsusSemaglutide | 11 | $18,492 |
| Spiriva HandihalerTiotropium Bromide | 12 | $17,615 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Glassia, Gammagard Liquid | $7,818 | $377,16635 claims |
| PfizerOctagam, Eliquis | $78 | $314,73498 claims |
| Lilly USA, LLCMounjaro, Trulicity | $219 | $263,937186 claims |
| Novo NordiskOzempic, Rybelsus | $250 | $258,540150 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $123 | $67,58984 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $36 | $60,18780 claims |
| Johnson & JohnsonXarelto | $36 | $49,36132 claims |
| MerckJanuvia | $27 | $7,91012 claims |
| AbbVieSynthroid | $134 | $2,06434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Pensacola
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.